Top Markets
#1 Islamic Coin Islamic Coin +151.57%
#2 Black Phoenix Black Phoenix +35.61%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +20.18%
#4 Akedo Akedo +16.48%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +13.14%
#6 HOME HOME +13.04%
#7 Palladium Network Palladium Network +13.02%
#8 OpenEden OpenEden +12.72%
#9 clBTC clBTC +11.93%
#10 Fake World Assets Fake World Assets +11.04%
Coin of the day
Islamic Coin Islamic Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Nabriva Therapeutics plc Nabriva Therapeutics plc

Nabriva Therapeutics plc

NBRV
Classement en actions #39979
Nabriva Therapeutics plc is a biopharmaceutical company focused on the... Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.
Prix de l'action
$0.63
Dernière synchronisation: 2023-08-29
Capitalisation boursière
$284.20K
Changement (1 jour)
-21.25%
Changement (1 an)
0.00%
Pays
IE
Échange Nabriva Therapeutics plc (NBRV)

Catégorie

Healthcare
Bénéfices pour Nabriva Therapeutics plc (NBRV)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Nabriva Therapeutics plc, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Nabriva Therapeutics plc de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE